JP2017537941A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537941A5 JP2017537941A5 JP2017531577A JP2017531577A JP2017537941A5 JP 2017537941 A5 JP2017537941 A5 JP 2017537941A5 JP 2017531577 A JP2017531577 A JP 2017531577A JP 2017531577 A JP2017531577 A JP 2017531577A JP 2017537941 A5 JP2017537941 A5 JP 2017537941A5
- Authority
- JP
- Japan
- Prior art keywords
- fucnac
- mannac
- galnac
- pyr
- gal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001720 carbohydrates Chemical class 0.000 claims 11
- 241000894006 Bacteria Species 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 230000001681 protective effect Effects 0.000 claims 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 2
- 208000031729 Bacteremia Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 238000010324 immunological assay Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 0 C[C@](C(*)C1OC)OC(CO)C1O Chemical compound C[C@](C(*)C1OC)OC(CO)C1O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14197832 | 2014-12-12 | ||
| EP14197832.0 | 2014-12-12 | ||
| EP15163253 | 2015-04-10 | ||
| EP15163253.6 | 2015-04-10 | ||
| PCT/EP2015/060756 WO2016091399A1 (en) | 2014-12-12 | 2015-05-15 | Vaccines against streptococcus pneumoniae serotype 4 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537941A JP2017537941A (ja) | 2017-12-21 |
| JP2017537941A5 true JP2017537941A5 (enExample) | 2018-06-21 |
| JP6622804B2 JP6622804B2 (ja) | 2019-12-18 |
Family
ID=53267330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017531577A Active JP6622804B2 (ja) | 2014-12-12 | 2015-05-15 | ストレプトコッカス ニューモニアエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）血清型４に対するワクチン |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10188718B2 (enExample) |
| EP (1) | EP3230297B1 (enExample) |
| JP (1) | JP6622804B2 (enExample) |
| WO (1) | WO2016091399A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201803881RA (en) * | 2015-12-17 | 2018-06-28 | Max Planck Gesellschaft | Synthetic vaccines against streptococcus pneumoniae serotype 2 |
| JP7551618B2 (ja) | 2018-12-12 | 2024-09-17 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Ｏ－結合型グリコシル化のための修飾キャリアタンパク質 |
| WO2024110839A2 (en) | 2022-11-22 | 2024-05-30 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2025057078A1 (en) | 2023-09-14 | 2025-03-20 | Pfizer Inc. | Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102250099B1 (ko) * | 2013-07-07 | 2021-05-10 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | 스트렙토코커스 뉴모니에 1형에 대한 합성 백신 |
| EP2851092A1 (en) * | 2013-09-18 | 2015-03-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Protein and peptide-free synthetic vaccines against streptococcus pneumoniae type 3 |
| WO2016046420A1 (en) * | 2014-09-26 | 2016-03-31 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Vaccines against streptococcus pneumoniae serotype 8 |
| SG11201803881RA (en) * | 2015-12-17 | 2018-06-28 | Max Planck Gesellschaft | Synthetic vaccines against streptococcus pneumoniae serotype 2 |
-
2015
- 2015-05-15 EP EP15724583.8A patent/EP3230297B1/en active Active
- 2015-05-15 JP JP2017531577A patent/JP6622804B2/ja active Active
- 2015-05-15 US US15/534,676 patent/US10188718B2/en active Active
- 2015-05-15 WO PCT/EP2015/060756 patent/WO2016091399A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wen et al. | Molecular epidemiology and evolution of Haemophilus influenzae | |
| JP2017532321A5 (enExample) | ||
| Jedrzejas | Pneumococcal virulence factors: structure and function | |
| Sethi | Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon? | |
| Gunn et al. | Salmonella chronic carriage: epidemiology, diagnosis, and gallbladder persistence | |
| Ogunniyi et al. | The genes encoding virulence-associated proteins and the capsule of Streptococcus pneumoniae are upregulated and differentially expressed in vivo | |
| JP2020533438A5 (enExample) | ||
| JP2020533439A5 (enExample) | ||
| JP2020533437A5 (enExample) | ||
| JP2020533442A5 (enExample) | ||
| JP2021535921A (ja) | 多価肺炎球菌ワクチン | |
| JP2017537941A5 (enExample) | ||
| Adamu et al. | Membrane proteins of Mycoplasma bovis and their role in pathogenesis | |
| IL274500B2 (en) | Glycoconjugation process | |
| BRPI0920460A2 (pt) | eixo de torcao com espessura de parede variavel longitudinalmente | |
| FI3110441T3 (fi) | Uusi polysakkaridi ja sen käyttöjä | |
| JP2016040284A5 (enExample) | ||
| EA200801374A1 (ru) | Вакцина | |
| CN111065417B (zh) | 免疫原性组合物 | |
| JP2015521202A5 (enExample) | ||
| François et al. | Antibody-based therapy to combat Staphylococcus aureus infections | |
| JP2016526564A5 (enExample) | ||
| Mirzaei et al. | Synthesis of conjugated PIA–rSesC and immunological evaluation against biofilm-forming Staphylococcus epidermidis | |
| JP2011504535A5 (enExample) | ||
| Nieddu et al. | PCV13 serotype decrease in Italian adolescents and adults in the post-PCV13 era: Herd protection from children or secular trend? |